Not applicableUnknownNCT05383014What this trial is testingFLT3-ITD Gene Mutation and CD135 Expression in Acute Myeloid Leukemia.Who this might be right forAcute Myeloid Leukemia Assiut University 82
Large-scale testing (Phase 3)Study completedNCT02997202What this trial is testingA Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)Who this might be right forAcute Myeloid Leukemia Astellas Pharma Global Development, Inc. 356
Testing effectiveness (Phase 2)Ended earlyNCT04240002What this trial is testingGilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)Who this might be right forAcute Myeloid Leukemia (AML)Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation / Internal Tandem Duplication (ITD) Astellas Pharma Global Development, Inc. 9
Testing effectiveness (Phase 2)Study completedNCT01883362What this trial is testingStandard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AMLWho this might be right forAcute Myeloid Leukemia Novartis Pharmaceuticals 60
Large-scale testing (Phase 3)Study completedNCT02668653What this trial is testingQuizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)Who this might be right forAcute Myeloid LeukemiaLeukemia Daiichi Sankyo 539
Testing effectiveness (Phase 2)Study completedNCT01830361What this trial is testingTrial to Assess the Efficacy of Midostaurin (PKC412) in Patients With c-KIT or FLT3-ITD Mutated t(8;21) AMLWho this might be right forAcute Myeloid Leukemia Technische Universität Dresden 18
Large-scale testing (Phase 3)Not Yet RecruitingNCT07425808What this trial is testingFLT3-ITD Targeted Therapy in Fit AML PatientsWho this might be right forAML (Acute Myeloid Leukemia) European Organisation for Research and Treatment of Cancer - EORTC 230
Testing effectiveness (Phase 2)Ended earlyNCT03735875What this trial is testingVenetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid LeukemiaWho this might be right forAcute Myeloid Leukemia With FLT3/ITD MutationRecurrent Acute Myeloid LeukemiaRefractory Acute Leukemia M.D. Anderson Cancer Center 8
Large-scale testing (Phase 3)Study completedNCT01371981What this trial is testingBortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaWho this might be right forAcute Myeloid LeukemiaLeukemia CutisMyeloid Neoplasm+1 more National Cancer Institute (NCI) 1,645
Testing effectiveness (Phase 2)WithdrawnNCT02723435What this trial is testingMidostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-TransplantWho this might be right forAcute Myeloid Leukemia With Gene MutationsAdult Acute Myeloid Leukemia in Remission Stanford University
Not applicableNo Longer AvailableNCT02624570What this trial is testingMidostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation ChemotherapyWho this might be right forAcute Myeloid Leukemia (AML) WithFLT3 Mutation, Internal Tandem Duplication (ITD) or Tyrosine Kinase Domain (TKD) Novartis Pharmaceuticals
Testing effectiveness (Phase 2)Ended earlyNCT03333486What this trial is testingFludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood CancerWho this might be right forAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAcute Leukemia in RemissionAcute Lymphoblastic Leukemia+34 more Roswell Park Cancer Institute 31
Early research (Phase 1)Study completedNCT01578109What this trial is testingSorafenib Tosylate Before and After Donor Bone Marrow Transplant in Treating Patients With Acute Myeloid LeukemiaWho this might be right forAcute Myeloid Leukemia With FLT3/ITD Mutation National Cancer Institute (NCI) 51
Testing effectiveness (Phase 2)Ended earlyNCT02634827What this trial is testingMidostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 MutationWho this might be right forAcute Myeloid Leukemia With FLT3/ITD MutationAcute Myeloid Leukemia With Gene MutationsFLT3 Tyrosine Kinase Domain Point Mutation+2 more Mayo Clinic 1
Testing effectiveness (Phase 2)Ended earlyNCT04209725What this trial is testingCPX-351 (Vyxeos™) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid LeukemiaWho this might be right forLeukemia, Myeloid, Acute SCRI Development Innovations, LLC 1
Not applicableUnknownNCT02156297What this trial is testingSorafenib to Treat FLT3-ITD AMLWho this might be right forAcute Myeloid LeukemiaFLT3-ITD Mutation The First Affiliated Hospital of Soochow University 100
Early research (Phase 1)Looking for participantsNCT06222580What this trial is testingSNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 MutationWho this might be right forAcute Myeloid Leukemia With FLT3/ITD MutationAcute Myeloid Leukemia With KMT2A RearrangementAcute Myeloid Leukemia With NPM1 Mutation+2 more Uma Borate 30
Not applicableNo Longer AvailableNCT03746912What this trial is testingExpanded Treatment Protocol for Adults With FLT3-ITD Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) to Receive QuizartinibWho this might be right forAcute Myeloid Leukemia With Gene Mutations Daiichi Sankyo
Testing effectiveness (Phase 2)Study completedNCT00553202What this trial is testingDonor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous LeukemiaWho this might be right forLeukemia Children's Oncology Group 158
Testing effectiveness (Phase 2)Looking for participantsNCT07259707What this trial is testingGilteritinib Plus VA Followed By Consolidation Chemotherapy in Newly Diagnosed FLT3-ITD+ AMLWho this might be right forAcute Myeloid LeukemiaFLT3 Internal Tandem Duplication PositiveIntermediate Risk Acute Myeloid Leukemia+1 more First Affiliated Hospital of Zhejiang University 25